Best responses from 50mcg dosed patients, so moving into Ph2 on this dose, with no safety issues reported from Ph1. I’m hoping response rates will be better in ph2 now that they have worked out the optimal dose from Ph1. Trial is expected to run 6 months, so not that far away.
I was really happy to see IMU article in US Pharma Industry publication this morning. I think this will bring IMU some International attention from the general population, not just those who attend conferences.
Best responses from 50mcg dosed patients, so moving into Ph2 on...
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 3.9¢ | 3.7¢ | $388.1K | 10.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 146314 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 2536521 | 6 |
View Market Depth
| Last trade - 16.10pm 02/12/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
